Dermira, Inc.

Dermira, Inc.

Dermira, Inc.

Overview
Date Founded

2010

Headquarters

2055 Woodside Road,Suite 270,Redwood City, CA 94061

Type of Company

Public

Employees (Worldwide)

101 - 250

Industries

Pharmaceuticals
Biotechnology

Company Description

Dermira, Inc. is a biopharmaceutical company, which engages in the provision of therapies for chronic skin conditions. The company was founded by Thomas G. Wiggans, Eugene Andrew Bauer, Luis C. Peña, and Christopher M. Griffith in 2010 and is headquartered in Menlo Park, CA.

Contact Data
Trying to get in touch with decision makers at Dermira, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Senior Vice President-Pharmaceutical Sciences

Chief Executive Officer

President & Director

Chief Business Officer & Senior Vice President

Head of Corporate Communications

Senior Director

Director

Coordinator

Director of Technology

Director

Board of Directors

Treasurer & Senior Vice President-Finance at Eli Lilly & Company

President & Director at Dermira, Inc.

Director at Dermira, Inc.

Paths to Dermira, Inc.
Potential Connections via
Relationship Science
You
Dermira, Inc.
Recent Transactions
Details Hidden

Eli Lilly & Company purchases Dermira, Inc.

Details Hidden

Dermira, Inc. issued . USD Common Stock

Details Hidden

Dermira, Inc. raised money in a private placement transaction

Transaction Advisors
Investment Advisor

Advised onEli Lilly & Company purchases Dermira, Inc.

Underwriter

Advised onDermira, Inc. issued USD Common Stock

Underwriter

Advised onDermira, Inc. issued USD Common Stock

Associate

Advised onEli Lilly & Company purchases Dermira, Inc.

Associate

Advised onEli Lilly & Company purchases Dermira, Inc.

Legal Advisor

Advised onDermira, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner, San Diego at Cooley LLP

Scientific Advisor

Chair, Dermatology at NYU Elaine A. & Kenneth G. Langone Medical Center

Scientific Advisor

Director, Occupational & Environmental Dermatology at New York University - School of Medicine

Clients

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.

Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases. The company was founded in 1943 and is headquartered in Barcelona, Spain.

Maruho Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceutical products. It specializes in the production of dermatology and topical drugs. Its products include Hirudoid Cream, Eksalb, Rozex Gel, Casal Cream, Farom Tablets, and Telgin G Dry Syrup. The company was founded by Eikuma Koba in July 1915 and is headquartered in Osaka, Japan.

Key Stats and Financials As of
Market Capitalization
$1.04B
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Investors
Details Hidden

FMR uses a variety of methods of security analysis in managing client assets to select investments including fundamental analysis, quantitative analysis and cyclical analysis. The firm also uses general macro-economic analysis as a component of its security analysis methods. When it comes to the management of the client assets according to the investment objectives, they utilize a variety of investment strategies including, but not limited to, investing in stocks and other public and private equity securities, bonds and other debt securities of all types and repurchase agreements for those securities, real estate related investments of all types, derivatives, currency spot and forward trading, other investment funds, including exchange traded funds and FMR’s or its affiliates’ central funds. The firm also engages in securities lending to parties such as broker-dealers or other institutions.

Details Hidden

FMR help over 32 million people feel more confident in their most important financial goals, manage employee benefit programs for over 22,000 businesses, and support more than 13,000 financial institutions with innovative investment and technology solutions to grow their businesses.

Details Hidden

Chairman-Vant Division at Roivant Sciences, Inc.

Suppliers
Roche Holding AG Hospitals & Patient Services | Basel, Switzerland

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Takeda Pharmaceutical Co., Ltd. Chemicals | Osaka, Japan

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Bausch Health Cos., Inc. Pharmaceuticals - Laval, Canada

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

AstraZeneca Plc Pharmaceuticals - Cambridge, United Kingdom

AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. Its pipeline are used for the following therapy areas: oncology, cardiovascular, renal, metabolism, and respiratory. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Dermira, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Dermira, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Dermira, Inc..